Stock data
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of US$0.00M and net income of -US$144.74M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.00M | — | -US$153.29M | -US$144.74M | — |
| 2024 | US$87.37M | — | -US$314.73M | -US$301.74M | — |
| 2023 | US$380.79M | — | US$38.80M | US$49.27M | — |
| 2022 | US$22.23M | — | -US$201.34M | -US$198.38M | — |
| 2021 | US$0.28M | — | -US$82.69M | -US$87.93M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$43.42M | — |
| 2026-03-31 | — | -US$41.28M | — |
| 2025-12-31 | US$0.00M | -US$33.00M | — |
| 2025-09-30 | US$0.00M | -US$34.39M | — |
| 2025-06-30 | US$0.00M | -US$41.44M | — |
| 2025-03-31 | US$0.00M | -US$35.91M | — |
| 2024-12-31 | -US$0.67M | -US$37.55M | — |
| 2024-09-30 | US$0.42M | -US$72.70M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.